Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compound for targeted ubiquitinated degradation of Smad3

A compound, ubiquitination technology, applied in the direction of peptides, etc., can solve the problem of not being an anti-fibrotic therapeutic target

Active Publication Date: 2015-11-25
THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIV
View PDF3 Cites 39 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patented inventor describes how we use special chemicals called Ubimodermolide or another substance found on proteins like smads to help them break down by removing certain parts from their DNA. These compositions have potential uses such as prevention of fibrous tissue formation caused by enzymes involved with inflammatory processes. They may be used alone or combined together to create drugs useful against this disease process.

Problems solved by technology

Technologies described involve combining certain types of components together like other parts involved in cellular communication processes. These techniques aim to enhance the function of these components while reducing their impact upon normal physiology functions. One technique involves linking them directly onto each other without involving another component. Another approach includes modifying existing ones either alone or combined with others to achieve desired effects. Overall, these technics help identify new targets related to various diseases including cancer metabolism, inflammations, neurologiscium release associated disorders, cardiac disease, muscle dystrophagy, renal failure, autoimmune response syndrome, diarrhexis due to bacterial overgrowth, arteriosclerosis, tissue remodeling, tumor growth, spine osteoporosis, pulmonary hypertension, heart attacks caused by excessive extracelluarcylation, autosomal dominant gene silencing system, apoptotic bodies containing both DNAbinding sites and non-DNA binding moieties, and membrane localization systems utilizing drug delivery mechanisms have been developed.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound for targeted ubiquitinated degradation of Smad3
  • Compound for targeted ubiquitinated degradation of Smad3
  • Compound for targeted ubiquitinated degradation of Smad3

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Embodiment 1: The construction method of the compound targeting ubiquitination and degrading Smad3 of the present invention (the compound described here is called Protac)

[0035] 1. The method for constructing the compound Protac targeting ubiquitination and degrading Smad3 according to the present invention

[0036] ① Determination of Smad3 active site and preparation of Smad3 protein;

[0037] ② Enamine compound library preparation;

[0038] ③Glide step-by-step screening based on molecular docking;

[0039] ④ Hits results and analysis;

[0040] ⑤ Further screening of small molecules by Surface Plasmon Resonance (SPR) technology;

[0041] ⑥Construction and chemical synthesis of Protac;

[0042] ⑦Verification of Protac peptide structure.

[0043] 2. Construction results

[0044] (1) Determination and preparation of the active site of Smad3

[0045] The establishment of the active site of Smad3 is the prerequisite for molecular simulation. The ROC1-SCFFbw1a comp...

Embodiment 2

[0087] Example 2: Verification of the degradation of Smad3 by targeting the ubiquitination pathway of the compounds targeting ubiquitination and degradation of Smad3 according to the present invention

[0088] Cell culture: DMEM medium for human renal carcinoma cell line (ACHN) and rat normal renal fibroblast cell line (NRK-49F), human renal clear cell adenocarcinoma cell line (786-0) and human glomerular mesangium 1640 medium for cell line (HMC), both containing 10% calf serum, 50×10 3 U / L penicillin and 50mg / L streptomycin at 37°C, 5% CO 2 Under normal subculture conditions.

[0089] Western detection of VHL protein expression: Collect 786-0, ACHN, NRK-49F and HMC cells in a 100mm cell culture dish, rinse twice with PBS on ice, add 1ml RIPA cell lysate (Millipore, USA), and lyse on ice for 20min. Centrifuge at 13000 rpm for 15 minutes, take 50 μl of supernatant, add 25 μl of 3×SDS loading buffer and boil for 8 minutes. Centrifuge at 13,000rpm for 15min, take 20 μl of the su...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention provides a compound for targeted ubiquitinated degradation of Smad3. The compound for targeted ubiquitinated degradation of Smad3 is formed by connecting a compound shown in a formula (I) and an ubiquitin ligase E3 identifying ligand shown in a formula (II) through a Linker shown in a formula (III) for connecting the two. The invention constructs a compound which can be specifically combined with Smad3 to degrade Smad3 proteins in a targeted manner through ubiquitination by jointly applying computer virtual screening and a technology of target ubiquitinated degradation of proteins, and the compound is verified to be capable of degrading Smad3 in a targeted ubiquitinated manner. As Smad3 is the major known fibrosis-inducing signaling protein, the Protac theoretically has an anti-fibrosis effect. Moreover, the molecular weight of the compound is small, so that the Protac can get into or out of cells freely, and therefore, the compound is likely to become a novel drug for treating fibrosis. The compound not only has scientific value, but also has important social value.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Owner THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products